Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study

Ocugen Inc OCGN has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.
The data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.
OCU200 is a biologic product candidate in preclinical development for sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD).
OCU200 inhibited cell proliferation, cell invasion, and tube formation by endothelial cells.
In the oxygen-induced retinopathy (OIR) mice model, OCU200 significantly reduced avascular areas at a low dose (68% reduction) and high dose (68% reduction). The observed difference in both doses was not much.
Also, significantly reduced neovascular tufts (NVs) at a low dose (59% reduction, P < 0.05) and high dose (58% reduction, P < 0.05) compared to vehicle-treated eyes, was observed.
Regeneron Pharmaceuticals Inc's REGN Eyelea (aflibercept) reduced NVs by 77%. OCU200 (10 ug) showed comparable activity to aflibercept (20 ug).
Price Action: OCGN shares fell 12.6% at $9.54 during the market trading session on the last check Thursday.